Audinot Valérie, Bonnaud Anne, Grandcolas Line, Rodriguez Marianne, Nagel Nadine, Galizzi Jean-Pierre, Balik Ales, Messager Sophie, Hazlerigg David G, Barrett Perry, Delagrange Philippe, Boutin Jean A
Division de Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, 125 chemin de Ronde, 78290 Croissy-sur-Seine, France.
Biochem Pharmacol. 2008 May 15;75(10):2007-19. doi: 10.1016/j.bcp.2008.02.022. Epub 2008 Mar 4.
In order to interpret the effects of melatonin ligands in rats, we need to determine their activity at the receptor subtype level in the corresponding species. Thus, the rat melatonin rMT(1) receptor was cloned using DNA fragments for exon 1 and 2 amplified from rat genomic DNA followed by screening of a rat genomic library for the full length exon sequences. The rat rMT(2) receptor subtype was cloned in a similar manner with the exception of exon 1 which was identified by screening a rat genomic library with exon 1 of the human hMT(2) receptor. The coding region of these receptors translates proteins of 353 and 364 amino acids, respectively, for rMT(1) and rMT(2). A 55% homology was observed between both rat isoforms. The entire contiguous rat MT(1) and MT(2) receptor coding sequences were cloned, stably expressed in CHO cells and characterized in binding assay using 2-[(125)I]-Iodomelatonin. The dissociation constants (K(d)) for rMT(1) and rMT(2) were 42 and 130 pM, respectively. Chemically diverse compounds previously characterized at human MT(1) and MT(2) receptors were evaluated at rMT(1) and rMT(2) receptors, for their binding affinity and functionality in [(35)S]-GTPgammaS binding assay. Some, but not all, compounds shared a similar binding affinity and functionality at both rat and human corresponding subtypes. A different pharmacological profile of the MT(1) subtype has also been observed previously between human and ovine species. These in vitro results obtained with the rat melatonin receptors are thus of importance to understand the physiological roles of each subtype in animal models.
为了解褪黑素配体在大鼠体内的作用,我们需要在相应物种中确定它们在受体亚型水平上的活性。因此,使用从大鼠基因组DNA中扩增的外显子1和2的DNA片段克隆大鼠褪黑素rMT(1)受体,随后筛选大鼠基因组文库以获取全长外显子序列。大鼠rMT(2)受体亚型以类似方式克隆,不同之处在于外显子1是通过用人hMT(2)受体的外显子1筛选大鼠基因组文库来鉴定的。这些受体的编码区分别翻译出rMT(1)和rMT(2)的353和364个氨基酸的蛋白质。在两种大鼠异构体之间观察到55%的同源性。完整的连续大鼠MT(1)和MT(2)受体编码序列被克隆,在CHO细胞中稳定表达,并使用2-[(125)I]-碘褪黑素进行结合测定表征。rMT(1)和rMT(2)的解离常数(K(d))分别为42和130 pM。对先前在人MT(1)和MT(2)受体上表征的化学性质多样的化合物在rMT(1)和rMT(2)受体上进行评估,以确定它们在[(35)S]-GTPγS结合测定中的结合亲和力和功能。一些但不是所有化合物在大鼠和人相应亚型上具有相似的结合亲和力和功能。先前在人和羊物种之间也观察到MT(1)亚型不同的药理学特征。因此,用大鼠褪黑素受体获得的这些体外结果对于理解动物模型中每个亚型的生理作用很重要。